NIKKEI 225
28,942.14 -280.63 (-0.96%) HANG SENG
19,763.91 -158.54 (-0.80%) CRUDE OIL
90.75 +0.25 (+0.28%) GOLD FUTURES
1,772.30 +1.10 (+0.06%) DOW
33,999.04 +18.72 (+0.06%) BTC-GBP
19,454.78 -175.52 (-0.89%)
GSK Aug 2022 43.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 43.00 |
| Expiry date | 2022-08-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 389 |
- Zacks
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
- Yahoo Finance Video
Plaintiff drops suit in first Zantac trial
Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.
- Reuters
Plaintiff in first Zantac lawsuit set for trial drops case
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.
